Exelixis | EXEL - 股本和储备



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 14.17B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


股本和储备 更改 日
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Agios Pharmaceuticals USD 1.11B 84M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Bayer EUR 28.85B 2.9B 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Cytokinetics USD -826.57M 166.94M 2026-03
Eisai JPY 898.99B 9.36B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Esperion Therapeutics USD -307.93M 5.97M 2026-03
Exelixis USD 1.94B 225.57M 2026-03
Genmab DKK 5.85B 96M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.62B 455.37M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Merck USD 45.88B 6.73B 2026-03
Moderna USD 7.41B 1.24B 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sanofi EUR 71.71B 14.25B 2025-12
Takeda JPY 7.77T 129.5B 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Xencor USD 515.63M 119.95M 2026-03